Health-related quality of life in HCV-infected patients

Current Hepatitis Reports

Volumn 6, Issue 4, 2007, Pages 169-175

  Groessl, Erik J ^a   Weingart, Kimberly R ^b   Kaplan, Robert M ^b   Ho, Samuel B ^b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MIXED INFECTION; QUALITY OF LIFE; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 37049003061     PISSN: 15403416     EISSN: 15410706     Source Type: Journal    
DOI: 10.1007/s11901-007-0020-9     Document Type: Review

References (45)

1. Heintges T, Wands JR: Hepatitis C virus: epidemiology and transmission. Hepatology 1997, 26:521-526.
2. Centers for Disease Control and Prevention: Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998, 47:1-39.
3. Hadziyannis SJ, Sette H Jr, Morgan TR, et al.: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-355.
4. Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
5. Falck-Ytter Y, Kale H, Mullen KD, et al.: Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002, 136:288-292.
6. Bini EJ, Brau N, Currie S, et al.: Prospective multicenter study of eligibility for antiviral therapy among 4084 US veterans with chronic hepatitis C virus infection. Am J Gastroenterol 2005, 100:1772-1779.
7. Butt AA, Justice AC, Skanderson M, et al.: Rate and predictors of treatment prescription for hepatitis C. Gut 2007, 56:385-389.
8. Cheung RC, Cunningham BA, Cooper AD: Effectiveness of a screening program for hepatitis C. Dig Dis Sci 2006, 51:976-981.
9. Shatin D, Schech SD, Patel K, McHutchison JG: Population-based hepatitis C surveillance and treatment in a national managed care organization. Am J Manag Care. 2004, 10:250-256.
10. Guillemin F: Functional disability and quality-of-life assessment in clinical practice. Rheumatology (Oxford) 2000, 39(Suppl 1):17-23.
11. Wolfe F, Pincus T: Listening to the patient: a practical guide to self-report questionnaires in clinical care. Arthritis Rheum 1999, 42:1797-1808.
12. Kaplan RM, Anderson JP: The quality of well-being scale: rationale for a single quality of life index. Presented at Centre for Medicines Research Workshop, CIBA Foundation. Lancaster, UK; March 5, 1988.
13. World Health Organization: Constitution of the World Health Organization. In Basic Documents. Geneva, Switzerland: WHO; 1948.
14. Kaplan RM, Bush JW: Health-related quality of life measurement for evaluation research and policy analysis. Health Psychol 1982, 1:61-80.
15. Kaplan RM, Bush JW, Berry CC: Health status: types of validitv and the index of well-being. Health Serv Res 1976, 11:478-507.
16. Spilker B: Introduction. In Quality of Life and Pharmacoeconomics in Clinical Trials, edn 2. Edited by Spilker B. Philadelphia: Lippincott-Raven; 1996:1-10.
17. • Spiegel BM, Younossi ZM, Hays RD, et al.: Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005, 41:790-800. This review article uses a meta-analytic approach to examine the effect sizes of various differences in HRQOL among HCV-infected patients.
18. •• Strauss E, Dias Teixeira MC: Quality of life in hepatitis C. Liver Int 2006, 26:755-765. This review article provides helpful background information on assessing HRQOL in HCV patients and describes the results of previous studies as they relate to important issues in HCV care and research.
19. Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). 1. Conceptual framework and item selection. Med Care 1992, 30:473-483.
20. Younossi Z, Kallman J, Kincaid J: The effects of HCV infection and management on health-related quality of life. Hepatology 2007, 45:806-816.
21. Kang SC, Hwang SJ, Lee SH, et al.: Health-related quality of life and impact of antiviral treatment in Chinese patients with chronic hepatitis C in Taiwan. World J Gastroenterol 2005, 11:7494-7498.
22. Balfour L, Cooper C, Kowal J, et al.: Depression and cigarette smoking independently relate to reduced health-related quality of life among Canadians living with hepatitis C. Can J Gastroenterol 2006, 20:81-86.
23. Hollander A, Foster GR, Weiland O: Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C. Scand J Gastroenterol 2006, 41:577-585.
24. Kanwal F, Gralnek IM, Hays RD, et al.: Impact of chronic viral hepatitis on health-related quality of life in HIV: results from a nationally representative sample. Am J Gastroenterol 2005, 100:1984-1994.
25. Tsui JI, Bangsberg DR, Ragland K, et al.: The impact of chronic hepatitis C on health-related quality of life in homeless and marginally housed individuals with HIV. AIDS Behav 2007, 11:603-610.
26. Posthouwer D, Plug I, van der Bom JG, et al.: Hepatitis C and health-related quality of life among patients with hemophilia. Haematologica 2005, 90:846-850.
27. Thein HH, Butler T, Krahn M, et al.: The effect of hepatitis C virus infection on health-related quality of life in prisoners. J Urban Health 2006, 83:275-288.
28. von Wagner M, Lee JH, Kronenberger B, et al.: Impaired health-related quality of life in patients with chronic hepatitis C and persistently normal aminotransferase levels. J Viral Hepat 2006, 13:828-834.
29. •• Arora S, O'Brien C, Zeuzem S, et al.: Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life. J Gastroenterol Hepatol 2006, 21:406-412. This manuscript presents important data from a large trial of interferon-based treatment for HCV patients with persistently normal ALTs.
30. •• Bonkovsky HL, Snow KK, Malet PF, et al.: Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol 2007, 46:420-431. This paper presents data from a large trial that treated HCV patients with advanced fibrosis. HRQOI. data are presented in relation to SVRs, depression, and degree of fibrosis.
31. •• Lim JK, Cronkite R, Goldstein MK, Cheung RC: The impact of chronic hepatitis C and comorbid psychiatric illnesses on health-related quality of life. J Clin Gastroenterol 2006, 40:528-534. This article presents data from a large sample of HCV patients and studies the impact of comorbid psychiatric illness on HRQOL.
32. Dan AA, Martin LM, Crone C, et al.: Depression, anemia and health-related quality of life in chronic hepatitis C. J Hepatol 2006, 44:491-498.
33. Rowan PJ, Al-Jurdi R, Tavakoli-Tabasi S, et al.: Physical and psychosocial contributors to quality of life in veterans with hepatitis C not on antiviral therapy. J Clin Gastroenterol 2005, 39:731-736.
34. Ozkan M, Corapcioglu A, Balcioglu I, et al.: Psychiatric morbidity and its effect on the quality of life of patients with chronic hepatitis B and hepatitis C. Int J Psychiatry Med 2006, 36:283-297.
35. Bieliauskas LA, Back-Madruga C, Lindsay KL, et al.: Clinical relevance of cognitive scores in hepatitis C patients with advanced fibrosis. J Clin Exp Neuropsychol 2006, 28:1346-1361.
36. Kramer L, Hofer H, Bauer E, et al.: Relative impact of fatigue and subclinical cognitive brain dysfunction on health-related quality of life in chronic hepatitis C infection. AIDS 2005, 19(Suppl 3):S85-S92.
37. Danoff A, Khan O, Wan DW, et al.: Sexual dysfunction is highly prevalent among men with chronic hepatitis C virus infection and negatively impacts health-related quality of life. Am J Gastroenterol 2006, 101:1235-1243.
38. Gjeruldsen S, Loge JH, Myrvang B, Opjordsmoen S: Drug addiction in hepatitis C patients leads to a lower quality of life. Nord J Psychiatry 2006, 60:157-161.
39. Wright M, Grieve R, Roberts J, et al.: Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006, 10:1-113, iii.
40. Mathew A, Peiffer LP, Rhoades K, McGarrity TJ: Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha-2b and ribavirin. Health Qual Life Outcomes 2006, 4:30.
41. Teixeira MC, Ribeiro Mde F, Gayotto LC, et al.: Worse quality of life in volunteer blood donors with hepatitis C. Transfusion 2006, 46:278-283.
42. Kramer L, Bauer E, Funk G, et al.: Subclinical impairment of brain function in chronic hepatitis C infection. J Hepatol 2002, 37:349-354.
43. Cordoba J, Flavia M, Jacas C, et al.: Quality of life and cognitive function in hepatitis C at different stages of liver disease. J Hepatol 2003, 39:231-238.
44. Gallegos-Orozco JF, Fuentes AP, Gerardo AJ, et al.: Health-related quality of life and depression in patients with chronic hepatitis C. Arch Med Res 2003, 34:124-129.
45. Rodger AJ, Jolley D, Thompson SC, et al.: The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999, 30:1299-1301.